drugset / Trial / NCT01614067
Delayed Start to Ovarian Stimulation
Phase 4
Terminated
30 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-07
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganirelix | Protein / enzyme biologic | — | — |